All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

20 hours ago
Weekly

Ab­b­Vie tacks on a new warn­ing to Rin­voq la­bel as safe­ty frets crimp JAK class

Yesterday
Marketing

Pfiz­er, Am­gen and Janssen seek fur­ther clar­i­ty on FDA's new ben­e­fit-risk guid­ance

Yesterday
R&D
FDA+

Janet Wood­cock plots her fu­ture at FDA, with se­nior ad­vi­sor role to fall back on if Califf wins con­fir­ma­tion

Yesterday
FDA+

As­traZeneca nix­es $8B So­bi buy­out over fears a for­mer drug would be sold to ri­vals — re­port

Yesterday
Deals

Com­mon, Jamie Foxx among celebs stand­ing up for clin­i­cal tri­als in star-stud­ded can­cer group's pan­dem­ic push

2 days ago
Pharma
Marketing

Ex-Im­munomedics CFO charged with in­sid­er trad­ing, faces up to 20 years in prison af­ter al­leged­ly tip­ping off girl­friend and rel­a­tives of a PhI­II suc­cess

2 days ago
Pharma

A UK vac­cine cen­ter is on the mar­ket and field­ing of­fers from man­u­fac­tur­ing gi­ants

2 days ago
Manufacturing

British CD­MO Ster­ling part­ners up on low-cost man­u­fac­tur­ing of mol­nupi­ravir

2 days ago
Coronavirus
Manufacturing

Fu­ji­film Diosynth dumps an­oth­er $454M in­to its sup­ply chain, this time at a fa­cil­i­ty in the UK

2 days ago
Manufacturing

A qui­et Czech biotech bags $315M to dri­ve its blos­som­ing can­cer pipeline through the clin­ic

2 days ago
Financing

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

2 days ago
Pharma
Coronavirus

Watch out, Roche: No­var­tis inks $1.5B deal to chase down promi­nent Parkin­son’s tar­get

2 days ago
Deals

An­oth­er epigenome edit­ing start­up launch­es from a pair of the field’s long­time lead­ers

2 days ago
Startups
Cell/Gene Tx

Glax­o­SmithK­line, Ox­ford un­veil new part­ner­ship pit­ting buzzy R&D ad­vances against neu­ro­log­i­cal dis­ease

2 days ago
Deals
Discovery

As first Omi­cron case in US crops up, re­searchers won­der: Which an­ti­bod­ies, vac­cines will hold up?

3 days ago
Coronavirus

Glax­o­SmithK­line's friend­ly ‘shark tank’ crowd­sources ideas for mul­ti­ple myelo­ma, kicks off big­ger push

3 days ago
Pharma
Marketing

Mod­er­na los­es lat­est bat­tle in key vac­cine de­liv­ery patent fight as fed­er­al ap­peal falls flat

3 days ago
Coronavirus

Months af­ter shock­ing in­vestors with lung can­cer win, Be­yond­Spring's lead drug hits road­block at the FDA

3 days ago
FDA+

Sanofi snaps up new vac­cine can­di­date and de­vis­es mR­NA game plan around it — but not for what you think

3 days ago
Deals
Cell/Gene Tx

Ap­peals court puts the fi­nal nail in the cof­fin for Tec­fidera patent, adding to Bio­gen's bur­geon­ing set­backs

4 days ago
Pharma

Drug de­vel­op­ment 101: Gilead goes back to school with new pro­gram to at­tract Black and His­pan­ic stu­dents to phar­ma

4 days ago
Pharma
Marketing

As lead drug runs in­to a wall, De­ci­phera slims down its pipeline, puts 140 jobs on the chop­ping block

4 days ago
People
R&D

Start­ing from scratch: Vi­a­tris’ new brand, cul­ture set­tle in 1 year af­ter My­lan, Up­john merg­er

4 days ago
Pharma
Marketing
1234 Next page Last page